Advertisement
Advertisement
October 15, 2024
Microbot’s ACCESS-PVI Trial of Liberty Robotic System Completes Enrollment
October 15, 2024—Microbot Medical Inc. announced that it has completed enrollment and follow up for all patients in its ACCESS-PVI clinical trial of the Liberty endovascular robotic surgical system. The company advised it remains on track to file its 510(k) submission with the FDA by the end of 2024.
ACCESS-PVI is a prospective, multicenter, single-arm, trial evaluating the performance and safety of the Liberty system in patients undergoing peripheral vascular interventions. The results of the trial will be shared at a conference in early 2025.
The company also announced that it is accelerating its market launch strategy and building its commercial infrastructure, including hiring a seasoned health care executive to lead its sales efforts. Microbot advised that FDA clearance is expected during 2Q 2025.
Advertisement
Advertisement
